Immunocore Presents Phase 1 Data of Brenetafusp, an ImmTAC Bispecific Targeting PRAME, in Patients with Ovarian Cancer

Immunocore's Brenetafusp Demonstrates Promising Anti-tumor Activity in Patients with Ovarian Cancer

Immunocore, a leading player in the development of novel immunotherapies, has presented promising Phase 1 data for brenetafusp, its ImmTAC bispecific targeting PRAME, in patients with advanced or recurrent ovarian cancer. The findings were unveiled at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, held in Boston from November 8-12, 2023.

Encouraging Early Results in Heavily Pre-treated Patients

The Phase 1 study evaluated the safety and efficacy of brenetafusp in 25 heavily pre-treated patients with advanced or recurrent ovarian cancer. The results showed encouraging anti-tumor activity, with an overall response rate of 20%. Notably, four patients experienced complete responses, and seven achieved partial responses.

The median duration of response was 10.3 months, and the median progression-free survival was 7.3 months. The safety profile of brenetafusp was manageable, with the most common adverse events being cytokine release syndrome and skin reactions.

Novel Mechanism of Action with Potential for Broad Applications

Brenetafusp is an innovative ImmTAC (Immune-mobilizing monoclonal T-cell-activating construct) bispecific molecule that targets PRAME (Preferentially Expressed Antigen in Melanoma), a tumor-associated antigen expressed in various cancers, including ovarian cancer.

The unique mechanism of action of brenetafusp involves the simultaneous binding of its two antigen-binding domains to CD3 on T cells and PRAME on cancer cells. This triggers T-cell activation and tumor cell killing, offering a novel approach to cancer immunotherapy.

Promising Future for Brenetafusp in Ovarian Cancer Treatment

The Phase 1 data of brenetafusp in patients with ovarian cancer provide compelling evidence of its potential as a valuable therapeutic option. Further research is needed to confirm the efficacy and safety of brenetafusp in larger patient populations.

Immunocore is currently conducting a Phase 2 trial (NCT05105228) to further evaluate the efficacy and safety of brenetafusp in patients with ovarian cancer. The results of this trial are expected to provide additional insights into the potential of brenetafusp in treating this challenging disease.